Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

5 recruiting

Enrollment Performance

Analytics

Phase 2
5(62.5%)
Phase 1
3(37.5%)
8Total
Phase 2(5)
Phase 1(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials
NCT07413094Phase 2Recruiting

Efficacy and Safety of YD0743 Treatment for Sepsis-Associated ARDS

Role: lead

NCT07311369Phase 2Recruiting

Evaluate the Safety and Efficacy of HL-1186 Tablet for Postoperative Pain Management in Abdominal Surgery

Role: lead

NCT07147049Phase 2Recruiting

Evaluate the Safety and Efficacy of HL-1186 Tablet for Moderate to Severe Acute Pain After Surgery

Role: lead

NCT07174115Phase 2Recruiting

A Study to Evaluate the Efficacy and Safety of HTMC0658 Tablets in the Treatment of Chronic Rhinosinusitis Without Nasal Polyps

Role: lead

NCT07159243Phase 2Not Yet Recruiting

Evaluate the Efficacy and Safety of HL-1186 in Patients With Diabetic Peripheral Neuropathic Pain

Role: lead

NCT06912295Phase 1Recruiting

Assess the Safety, Tolerability, and Pharmacokinetics of HL-1186 in Healthy Participants

Role: lead

NCT07098091Phase 1Enrolling By Invitation

Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of YD0293 in Healthy Subjects

Role: lead

NCT05728619Phase 1Unknown

HTMC0435 and Temozolomide in Treating Patients With Small Cell Lung Cancer

Role: lead

All 8 trials loaded